Price (delayed)
$21.05
Market cap
$578.8M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$9.46
Enterprise value
$495.71M
graphite bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. the company’s platform harnesses the natural cellular process
There are no recent dividends present for LENZ.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.